There are currently 114 clinical trials in Chandler, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Ironwood Cancer and Research Centers SC, Chandler Regional Medical Center and Arizona Eye Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Chandler Clinical Research Trials- Site Number : 8400147, Chandler, Arizona
Conditions: Asthma
Register for Updates
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
NCT05039840
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/07/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler- Site Number : 8400026, Chandler, Arizona
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
NCT06812780
Recruiting
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/07/2025
Locations: Research Site, Chandler, Arizona
Conditions: Hepatic Impairment
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Site, Chandler, Arizona
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338
Recruiting
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/07/2025
Locations: Investigative Site, Chandler, Arizona
Conditions: Viral Hepatitis
Register for Updates
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089
Recruiting
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Clinical Site, Chandler, Arizona
Conditions: Arthritis, Psoriatic
Register for Updates
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Ironwood Cancer and Research Center, Chandler, Arizona
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Chandler, Arizona
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916
Recruiting
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the bra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona
Conditions: Melanoma
Register for Updates
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076
Recruiting
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Clinical Site, Chandler, Arizona
Conditions: Arthritis, Psoriatic
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Valley Heart Rhythm Specialists, Chandler, Arizona
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates